United Therapeutics (UTHR) Cash from Operations (2009 - 2026)

United Therapeutics has disclosed Cash from Operations across 18 years of filings, most recently posting $313.6 million for Q2 2026.

• In Q2 2026, Cash from Operations rose 63.59% year-over-year to $313.6 million; the TTM figure through Jun 2026 stood at $1.7 billion (up 22.89% YoY), while the FY2025 annual figure was $1.6 billion, up 17.64% from the prior year.
• Cash from Operations came in at $313.6 million for Q2 2026 at United Therapeutics, down from $463.3 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $562.1 million in Q3 2025 to a low of $106.3 million in Q2 2023.
• Average Cash from Operations over 5 years is $302.5 million, with a median of $327.4 million recorded in 2024.
• The largest YoY upside for Cash from Operations was 221.49% in 2022 against a maximum downside of 26.58% in 2022.
• Over 5 years, Cash from Operations stood at $128.2 million in 2022, then rose by 17.55% to $150.7 million in 2023, then soared by 126.41% to $341.2 million in 2024, then advanced by 1.47% to $346.2 million in 2025, then decreased by 9.42% to $313.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were $313.6 million in Q2 2026, $463.3 million in Q1 2026, and $346.2 million in Q4 2025.